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Abstract
The presence and location of resident pancreatic β-cell progenitors is controversial.
A subpopulation of insulin-expressing but glucose transporter-2-low (Ins+Glut2LO)
cells may represent multipotent pancreatic progenitors in adult mouse and in human
islets, and they are enriched in small, extra-islet β-cell clusters (<5 β cells) in mice.
Here, we sought to identify and compare the ontogeny of these cells in mouse and
human pancreata throughout life. Mouse pancreata were collected at postnatal days
7, 14, 21, 28, and at 3, 6, 12, and 18 months of age, and in the first 28 days after β-cell
mass depletion following streptozotocin (STZ) administration. Samples of human
pancreas were examined during fetal life (22–30 weeks gestation), infancy (0–1 year),
childhood (2–9), adolescence (10–17), and adulthood (18–80). Tissues were analyzed by
immunohistochemistry for the expression and location of insulin, GLUT2 and Ki67. The
proportion of β cells within clusters relative to that in islets was higher in pancreas of
human than of mouse at all ages examined, and decreased significantly at adolescence.
In mice, the total number of Ins+Glut2LO cells decreased after 7 days concurrent with the
proportion of clusters. These cells were more abundant in clusters than in islets in both
species. A positive association existed between the appearance of new β cells after the
STZ treatment of young mice, particularly in clusters and smaller islets, and an increased
proportional presence of Ins+Glut2LO cells during early β-cell regeneration. These data
suggest that Ins+Glut2LO cells are preferentially located within β-cell clusters throughout
life in pancreas of mouse and human, and may represent a source of β-cell plasticity.
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Introduction
Insulin-producing β cells to be utilized for the reversal of
diabetes may be theoretically derived from endogenous
pancreatic β-cell progenitors. However, the presence of
resident β-cell progenitors is controversial (Dor et al. 2004,
Seaberg et al. 2004, Nir et al. 2007, Teta et al. 2007, Xu et al.
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2008, Van de Casteele et al. 2013), especially as the tissue
origins of new β cells may differ with age (Solar et al.
2009, Salpeter et al. 2010, Stolovich-Rain et al. 2012),
pregnancy (Parsons et al. 1992, Sorenson & Brelje 1997),
obesity and impaired glucose tolerance (Porat et al. 2011,
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Chen et al. 2014) and experimental pancreatic injury
(Bonner-Weir et al. 2008, Inada et al. 2008). There is
evidence for rare pancreatic progenitor cells in human and
mouse islets capable of multi-lineage differentiation and
which express insulin (Smukler et al. 2011). Importantly,
these cells demonstrate low/absent glucose-transporter
2 (GLUT2), exhibit poor glucose-stimulated insulin
release, have a higher endogenous rate of proliferation
than mature β cells, and express transcription factors
normally associated with early endocrine development
(Smukler et al. 2011). Recently, we have demonstrated that
Ins+Glut2LO cells were enriched within the small extra-islet
pancreatic β-cell clusters (<5 β cells) as compared to prototypical islets (Beamish et al. 2016). Small β-cell clusters
have been previously assumed to be of minor physiological
importance. The relative abundance of the cells capable of
multi-lineage differentiation ranged from 1/1500 β-cells
within 7 days mouse islets as found by us (Beamish et al.
2016), to 1/10,000 in the adult human and mouse islet as
found by others in vitro (Smukler et al. 2011). On performing
immunohistochemistry of pancreas sections, it was found
that up to 3.5% of all β cells present in the 7-day mouse
pancreas express insulin but not GLUT2, the majority of
them being located outside of the islets. However, only
1/200 of such cells were capable of differentiation into
non-β-cell lineages. The non-lineage plastic Ins+GLUT2LO
cells then possibly representing immature and/or glucoseunresponsive β-cells in the developing postnatal pancreas.
It was further demonstrated that the total relative
proportion of these cells had decreased in adult mice. The
present study therefore sought to explore the anatomical
location, proliferation rate and change in abundance of
these Ins+Glut2LO cells across the lifespan in both mouse
and human pancreas, and the possible involvement of
these cells during compensatory β-cell regeneration in the
young mouse with diabetes.

Materials and methods
Human and mouse pancreas sample collection
Twenty-seven samples of human pancreas were assessed,
obtained as formalin-fixed and paraffin-embedded
tissue sections from the Department of Pathology
at Western University, Schulich School of Medicine
(London, Ontario, Canada), and the University of
Chicago (Chicago, Illinois, USA), with approval from the
Western University Research Ethics Board (#103167), the
Institutional Review Board at the University of Chicago,
http://joe.endocrinology-journals.org
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and Lawson Health Research Institute (R-12-501). Criteria
for inclusion were: pancreas samples should be selected
from transplant-quality cadaveric tissues taken from
donors with no known metabolic disease; body weight
within a BMI range of 18–25 kg/m2. Tissues utilized
were representative of diverse ethnic backgrounds, and
inclusive of both sexes (48% female, 13/27 samples).
Paraffin blocks were chosen from mid-pancreas whenever
possible, and human pancreas tissues were fixed
within 6–12 h of cold ischemia to control for changes
post-mortem.
All animal procedures were approved by the Western
University Animal Use Ethics Committee, in accordance
with the Canadian Council on Animal Care guidelines.
Forty-one samples of mouse pancreas from both sexes
(42% female, 17/41) were collected from our existing
colony with a C57Bl/6 genetic background. All mice were
maintained at the Lawson Health Research Institute,
St Joseph Health Care, London, Ontario, Canada with
food and water provided ad libitum. Mice were killed by
exposure to CO2 and pancreata were fixed and prepared
as previously described (Beamish et al. 2016).
Mouse and human tissues of various ages were chosen
to illustrate major developmental stages, including early
Table 1 Human pancreas samples.
Case no.

Sex

Age

Developmental stage

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

F
F
F
M
F
M
F
M
M
F
F
M
M
F
M
F
F
M
F
M
F
M
M
M
F
M
M

22 weeks G
30 weeks G
30 weeks G
2 days
11 days
14 days
5 years
6 years
6 years
6 years
9 years
10 years
11 years
14 years
19 years
20 years
28 years
36 years
41 years
50 years
52 years
54 years
56 years
65 years
72 years
72 years
79 years

Fetal
Fetal
Fetal
Infant
Infant
Infant
Child
Child
Child
Child
Child
Adolescent
Adolescent
Adolescent
Young adult
Young adult
Young adult
Young adult
Adult
Adult
Adult
Adult
Adult
Late adult
Late adult
Late adult
Late adult
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Adulthood
Gestaon Infancy Childhood Adolescence

Time
(years)

40 weeks 0–1

–

2–9

10–17

18–40

B
Sexual
Wean maturity

Gestaon Birth

Journal of Endocrinology

Time

21 days 0 day

7
14
21
28
days days days days

41–64

Adulthood

3
6
months months

endocrine pancreas development, infancy, childhood,
adolescence/sexual maturation, and early, mid, and
late adulthood; the characteristics of human sample are
shown in Table 1, and a schematic of life stages for both
species is shown in Fig. 1.

Induction of hyperglycemia by STZ
To assess the changes in the population of Ins+Glut2LO
cells following the induction of diabetes, streptozotocin
(STZ, Sigma) was injected on day 7 of age (100 μg/g body
weight, in 0.1 M citrate buffer). Control littermates
were injected with 0.1 M citrate buffer (Sham). Before
killing the mice, blood samples from the tail vein were
taken and glucose was measured after a 4-h fast using
a One Touch Ultra glucometer (Lifescan INC, Milpitas,
CA, USA). Mice were killed on days 9, 14, 21, or 28 of
age and pancreata were dissected and processed for
histological assessment.

Beta cell morphometry
Two pancreas sections per mouse were immunostained
with insulin as described previously (Cox et al. 2010), and
imaged and analyzed using the Northern Eclipse software
(v7.0; Empix Imaging, Mississauga, ON, Canada). Total
pancreas area was traced at 2.5× magnification, and
β-cell area was traced at 40× magnification by insulin
immunoreactivity. Beta-cell mass was calculated by
multiplying the fractional β-cell area by the weight of the
pancreas (mg).
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12
months

18
months

Figure 1
Lifespan of the mouse and human. The entire
lifespan was examined in human (A) and mouse (B),
with the ages of pancreatic tissue donor selected to
illustrate major developmental stages, including
early development, infancy, childhood/weaning,
puberty/sexual maturation, and adulthood, as
represented by each red star. When possible,
developmental points were matched. A significant
proportion of mouse islet development occurs
postnatally, such that 20-week gestation in humans
is analogous to postnatal day 8 in mice (Pan &
Wright 2011); n ≥ 4 mice, and ≥3 humans/star.

Fluorescent immunohistochemistry
Fluorescent immunohistochemistry was performed using
antibodies for insulin, GLUT2 and Ki67 as described
previously (Beamish et al. 2016). GLUT2 immunostaining
in human pancreas samples required tyramide signal
amplification (TSA) (Perkin Elmer) (McCulloch et al. 2011).
Ki67 antigen visualization required antigen retrieval at
95°C in Tris-EDTA buffer for 30 min.
Tissue slides were imaged using a Zeiss LSM 510 Duo
Vario confocal microscope (Carl Zeiss) at the Biotron
Facility, Western University, and counted manually using
the Zen software. Every β cell was counted per section,
with minimum inclusion criteria being >300 insulin+ β
cells/section for mice (≥2 sections per pancreas, average
714 β cells from at least 10 islets, average 15.6 islets per
section), and >1200 insulin+ β cells/section of human
pancreas (1–2 sections per pancreas from 1 block, average
1933 β cells from at least 20 islets counted, average 48.9
islets). Controls were determined by cutting replicate
sections from the same block (>100 μm apart), and
variance around the mean was <9%.
Statistical analysis
At least quadruplicate pancreata were analyzed for mouse
and triplicate pancreata were analyzed for human samples
per cohort per life stage (Table 1). Data are presented
as percentage (%) mean ± s.e.m. of insulin+ β-cells, with
statistics performed using the ANOVA-R and Tukey’s
post-test, or student’s t-test, and with an acceptable level
of significance of P < 0.05. Beta-cell proliferation index
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Figure 2
Beta cell cluster proportion decreases with age
in mouse (A) and human (B) pancreas. Similar
developmental points were grouped (day 7
(mouse) and fetal (human) samples, open bars;
pre-weaning and sexual maturation (1428 days) (mouse) and infancy/childhood/
adolescence (human) samples, hatched bars; all
adult time points, black bars). Beta cells were
counted and allocated to the cluster (<5 β cells
together) or islet (>5 β cells) compartments.
(C, D, E) Representative images from human
pancreas immunostained with insulin (green)
illustrate changes during the maturation of islet
structures, from fetal life (C, 30-week gestation
female), puberty (D, 14-year-old female), and
late adulthood (E, 72-year female). Data
represent mean ± s.e.m. proportion (%) of total
β-cells counted; *P < 0.05, **P < 0.01,
***P < 0.001 vs day 7 in mouse, and fetal in
human; n > 3. Size bar denotes 50 μm.
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Figure 3
Insulin and GLUT2 immunostaining in human and
mouse pancreas. Representative images of a
human islet (A) and β-cell cluster (B) stained for
insulin (green) and GLUT2 (red). Human
Ins+Glut2LO cells are shown in B (arrows).
Proto-typical membrane immunostaining for
GLUT2 (red) and cytoplasmic insulin (green) in a
mouse islet (C), as well as an Ins+Glut2LO cell in a
mouse cluster (C, arrow). The non-membrane
immunostaining of human GLUT2 was previously
demonstrated by others (McCulloch et al. 2011),
an effect of the TSA kit protocol. Size bar
represents 50 μm.
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was assessed by non-linear regression. Statistical analysis
was performed using the GraphPad Prism software
(v. 5.01).

Results
β-cell cluster proportion decreases with age in mouse
and human pancreas
Pan and Wright showed that mice display significant
postnatal development of the endocrine pancreas,
such that P8 mouse pancreas is analogous to a 22-week
gestation human fetal pancreas (Pan & Wright 2011).
Thus, these time points were chosen to begin the
analysis. At day 7, 16.1 ± 0.8% of mouse β cells were
http://joe.endocrinology-journals.org
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C

Figure 4
The Ins+Glut2LO cell proportion decreases with
age. Percent Ins+Glut2LO cells relative to
proportion of total β cells (A, B), islets (C, D), and
clusters (E, F) as found in mouse (A, C, E) and
human (B, D, F) pancreas. Data represent
mean ± s.e.m.; *P < 0.05, **P < 0.01; ***P < 0.001 vs
day 7 (A, C) or vs fetal (B, D, F); t-test 3 months vs
21 days (E); n > 5.

located in extra-islet clusters (Fig. 2A, white bar).
This proportion decreased with advancing age, being
significantly reduced by 18 months to only 2.1 ± 0.7%;
the majority of β cells in the older animals being present
in proto-typical islets (Fig. 2A, black bar, 18 months
vs 7 day).
In contrast to mice, 41.6 ± 3.3% of human β cells
were located in clusters during the fetal life (Fig. 2B,
white bar, and Fig. 2C, immunostaining positive for
insulin (green)). This proportion was significantly larger
than the equivalent population in mice (fetal vs 7 day,
P < 0.0001, t-test). The relative proportion of β cells found
in clusters within human fetal pancreas at childhood
dropped significantly to 18.8 ± 4.6% respectively (Fig. 2B,
hatched bars), decreasing further to 5.5 ± 1.1% at puberty
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(Fig. 2B, hatched bar, fetal vs 10–17, P < 0.0001, and 2D).
Thereafter, the majority of human β cells were maintained
throughout the adulthood within islets (Fig. 2B, black
bars, and Fig. 2D). In early adulthood, there was a
significantly higher proportion of β cells present within

80

Figure 5
Frequency of β-cell proliferation decreases with
age. Proliferation of insulin-expressing β cells by
Ki67 presence is shown in total β cells (A, B), islets
(C, D), and clusters (E, F) within mouse (A, C, E)
and human (B, D, F) pancreas samples. Scatter
graphs show the spread of data points between
individual pancreata, and R2 values were
calculated using non-linear regression analysis.

clusters in samples of human females than in males
(11.0 ± 0.3% vs 4.3 ± 0.7% respectively, 18–41 years,
P < 0.05, t-test, not shown). By late adulthood, there were
very few β-cell clusters present within sections of human
pancreas (Fig. 2E).

Figure 6
Ins+Glut2LOKi67+ cells are enriched within β-cell clusters. A β-cell cluster within a human fetal pancreas section demonstrates an Ins+Glut2LOKi67+ cell
(arrow) immunostained for insulin (green, B), GLUT2 (red, A), and Ki67 (yellow, B). Size bar denotes 50 μm.
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0.5

Day
Figure 7
Partial regeneration of the endocrine pancreas in the young mouse
following STZ administration. Blood glucose (A) and β-cell mass (B)
following treatment with STZ on d 7 (closed circles/bars) or citrate buffer
(open circles/bars) for up to 28 days. Data represent mean ± s.e.m.;
*P < 0.05 vs day 7, *P < 0.05 vs control for same day; n > 5.

Ins+Glut2LO cell proportion decreases with age
We examined the population specifically of Ins+Glut2LO
cells over the lifespan of both human and mouse. Sections
of human pancreas demonstrated immunostaining for
insulin (green) and GLUT2 (red) in an islet as shown in
Fig. 3A. A representative image of human Ins+Glut2LO
cells is shown in Fig. 3B (arrows) within the β-cell cluster
compartment. The non-membrane immunostaining of
human GLUT2 was also shown by others (McCulloch et al.
2011), an effect of the TSA protocol. For comparison,
Fig.
3C
demonstrates
proto-typical
membrane
immunostaining for GLUT2 (red) and cytoplasmic insulin
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(green) in a mouse islet, as well as an Ins+Glut2LO cell in an
endocrine cluster (Fig. 3C, arrow).
In mice, the proportional presence of total Ins+Glut2LO
cells decreased significantly from 3.8 ± 0.8% at day 7
to 0.6 ± 0.2% at month 3 (Fig. 4A, 7 day vs 3 month,
P < 0.05), which decreased further by 18 months (Fig. 4A,
P < 0.001). In humans, this decrease was exaggerated, with
total Ins+Glut2LO cells proportionally declining after the
fetal life (Fig. 4B, fetal vs all others, P < 0.0001). There were
proportionally twice as many Ins+Glut2LO cells in pancreas
of human than that of mouse at the initial time point
studied (7.8 ± 0.9% fetal vs 3.8 ± 0.8% 7 days, P < 0.05).
The anatomical location of Ins+Glut2LO cells was then
examined. Figure 4C shows that 1.4 ± 0.5% of mouse
β cells within islets lacked GLUT2 at day 7 (white bar),
consistent with previous findings (Beamish et al. 2016).
This proportion significantly decreased by early adulthood
(0.4 ± 0.2%, 7 day vs 3 months, P < 0.001), where it was
maintained.
In humans, 1.1 ± 0.2% of the β cells within islets
demonstrated a lack of GLUT2 immunostaining during
the fetal life, which decreased significantly by childhood,
and further thereafter (Fig. 4D, fetal vs 10–17, P < 0.001).
There were few Ins+Glut2LO cells present in islets by late
adulthood in the human pancreas (Fig. 4D, 1.1 ± 0.2 vs
0.07 ± 0.01%, fetal vs 65+, P < 0.0001).
The proportion of Ins+Glut2LO cells within the cluster
compartment was markedly different than that within the
islet, with 16.1 ± 2.6% of all mouse insulin-expressing cells
lacking GLUT2 within clusters at day 7 (Fig. 4E), a peak at
day 21, but a subsequent decline thereafter (Fig. 4E, t-test
day 21 vs month 3).
In the human fetal pancreas, a similar proportion
of Ins+Glut2LO cells was found in β-cell clusters as in the
day 7 mouse (17.0 ± 1.7% vs 16.1 ± 2.6%, fetal vs day 7).
However, the Ins+Glut2LO cell proportional presence in
clusters was maintained throughout most of life, only
decreasing in late adulthood (Fig. 4F).

β-cell proliferation decreases with age
The proliferation index of total insulin+ β cells was
examined in mouse and human pancreas sections by
Ki67 immunostaining. Beta-cell proliferation was highest
at day 7 in the mouse and decreased thereafter, being
maintained after weaning at ~0.6% (Fig. 5A, R2 = 0.86).
In the human pancreas, a similar trend was noted, with
the highest total β-cell proliferation found in the fetal life,
which dropped thereafter (Fig. 5B, R2 = 0.54). There was
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Figure 8
The distribution of total β-cells, proliferating β-cells and Ins+Glut2LO cell abundance demonstrate ontological and anatomical differences during partial
regeneration of β-cell mass in the young mouse. Animals were treated with STZ on d 7 (closed bars) or vehicle alone (open bars) and subsequently
examined on days 9, 14, 21 or 28. The changes in the percentage of Ins+ cells in clusters (<5 β-cells, i), small islets (5–15 β-cells, ii) or larger islets (>15
β-cells, iii) are shown in A, the percentage of Ki67- labeled Ins+ cells in B, and the percentage of Ins+Glut2LO cells relative to all Ins+ cells in C. Within β-cell
clusters the relative number of Ins+ cells decreased with age in control, but not STZ-treated mice. In clusters from control mice the percent Ins+Ki67+ cells
significantly decreased with age, but not so after STZ treatment, whilst a transient increase in Ins+Ki67+ cells occurred in small and large islets at day 14
after STZ. The proportional presence of Ins+Glut2LO cells in clusters did not differ between control or STZ-treated mice, but were increased after STZ at
day 14 in both small and large islets. Data represent mean ± s.e.m.; *P < 0.05, **P < 0.01, ***P < 0.001 vs day 9; n > 5.

a significant variability in the prenatal and perinatal
samples, ranging from 0.9% to 2.3% and 0.2% to 0.9%,
respectively (Fig. 5B).
Proliferation of β cells within islets followed similar
patterns as was found for total cells, with rates of replicating
β-cells highest in mice at day 7, and which decreased
significantly by early adulthood (Fig. 5C, R2 = 0.86). In the
human pancreas, a comparable trend was found, with
proliferation of β cells being highest during the fetal life,
and decreasing thereafter (Fig. 5D, R2 = 0.39). There was
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considerable variability in the β-cell proliferation rate
within the islet in the fetal and infant samples, ranging
from 0.6% to 2.2% and 0.1% to 1.2%, respectively. After
adolescence the presence of β-cell proliferation within islets
was low but detectable at less than 0.5% of β-cells (Fig. 5D).
Within clusters, β-cell proliferation dropped
significantly in mice from day 7 to day 28 (Fig. 5E,
R2 = 0.52). Interestingly, this trend was not demonstrated
in human β-cell clusters, which showed variable
proliferation throughout life (Fig. 5F, R2 = 0.04).
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We have previously shown that Ins+Glut2LO cells have
a higher rate of proliferation than do GLUT2-expressing
insulin-positive cells in the neonatal life, particularly in
extra-islet clusters (Beamish et al. 2016). We extended
this analysis throughout life for both mouse and human
pancreas using Ki67 as a marker of DNA synthesis.
Consistent with our previous findings, 8.4 ± 4.2% of
proliferating β cells lacked GLUT2 in the islet, and
18.8 ± 4.9% in the clusters at day 7 in the mouse. At the
equivalent age in humans (fetal), 2/3 of pancreas samples
exhibited cells with an Ins+Glut2LOKi67+ phenotype
(3.3 ± 5.7% within islets vs 16.67 ± 15.74% within clusters,
7.9 ± 6.9% total). This distribution was maintained during
infancy (0–1 year, 14.1 ± 17.2% total, 2/3 samples), and
childhood (2–9 years, 6.9 ± 10.9% total, 2/4 samples).
Interestingly, 83.3% of these cells were found in clusters
in the human pancreas, and a similar 78.8% in the
mouse pancreas. After day 7 in the mouse and childhood
in the human, the proportion of Ins+Glut2LOKi67+ cells
diminished greatly, occurring rarely at all subsequent
ages, and predominantly in clusters. A representative
Ins+Glut2LOKi67+ cell within a fetal human pancreas
section is shown in Fig. 6 (arrow) immunostained for
insulin (green), GLUT2 (red) and Ki67 (yellow).

Changes in Ins+Glut2LO cell present during the β-cell
mass regeneration after neonatal STZ exposure
To assess the possible contribution of Ins+Glut2LO cells
to β-cell regeneration after the induction of diabetes,
neonatal (day 7) mice were treated with STZ. Analysis
was further sub-divided into three β-cell grouping-size
categories (clusters, <5 β cells; small islets, 5-15 β cells; and
large islets, >15 β cells), so as to identify dynamic changes
in the distribution during the β-cell regeneration in the
early post-natal mouse pancreas. Relative hyperglycemia
was noted 2 days after the STZ treatment and persisted
until day 21, but glucose levels were similar in STZ-treated
and control mice mice by day 28 (Fig. 7A). The presence
of hyperglycemia correlated with a 70% reduction of
β-cell mass after the STZ treatment compared to that of
control animals by day 14 (Fig. 7B). However, β-cell mass
was partially recovered and was not significantly different
between STZ-treated and control mice by day 28.
The proportion of Ins+ cells was determined within
clusters, small islets, or larger islets for STZ-treated or
control mice (Fig. 8A). Within clusters, the relative number
of Ins+ cells in control mouse pancreas significantly
decreased with age (Fig. 8A-i). This was not seen for clusters
http://joe.endocrinology-journals.org
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from STZ-treated mice, and at day 28 the percentage of
Ins+ cells was significantly higher than that in controls.
No age-related changes in the percentage presence of Ins+
cells within small or larger islets were observed in control
mice (Fig. 8A-ii and iii). At day 14 in STZ-treated animals
there was a significant decrease in the percentage of Ins+
cells present in larger islets, as would be expected and in
agreement with a reduced β-cell mass, but a significant
increase in percentage of Ins+ cell present in small islets in
the same tissues was observed.
We subsequently calculated the proportion of Ins+
cells undergoing DNA synthesis (Ki67+) from the same
pancreata (Fig. 8B). In clusters from control mice, the
percentage of Ins+Ki67+ cells significantly decreased with
age, but not so after the STZ treatment (Fig. 8B-i). Within
small and larger islets there was a significant but transient
increase in percentage of Ins+Ki67+ cells at day 14 after the
STZ treatment compared to control mice involving both
Ins+Glut2LO and Ins+Glut2HI cell populations (Fig. 8B-ii
and iii).
The abundance of specifically Ins+Glut2LO cells was
compared with all Ins+ cells (Fig. 8C). In agreement with
Fig. 4, the proportional presence of Ins+Glut2LO cells in
control mice increased within clusters until day 21, before
declining (Fig. 8C-i), and did not significantly differ after
the STZ treatment. However, in both small and large
islets there was a significant increase in the proportion of
Ins+Glut2LO cells at day 14 that was absent in control mice
(Fig. 8C-ii and iii). Thereafter, the population disappeared
by day 28 in small and large islets (Fig. 8C-ii and iii) but
was maintained in clusters (Fig. 8C-i).
These findings suggest that Ins+Glut2LO cells are not
destroyed by STZ, as would be expected since STZ enters
cells through GLUT2 transporters (Schnedl et al. 1994,
Wang & Gleichmann 1998). Ins+ cells were relatively more
abundant in clusters and in smaller islets after the STZ
treatment; and this was accounted for in part by a greater
presence of Ins+Glut2LO cells in islets in advance of β-cell
regeneration. This increase in Ins+Glut2LO cell abundance
was associated with increased β-cell proliferation and
suggests that they are dynamically linked to β-cell
renewal. It also suggests that the Ins+GlutLO cells matured
and coalesced from small β-cell clusters into islets.

Discussion
Over the mammalian lifespan, the endocrine pancreas
undergoes substantial changes in terms of cellular
maturity, function, replication ability, and cell
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macro-organization (Steiner et al. 2010). Previous
studies have shown that a population of Ins+Glut2LO,
lineage-plastic putative progenitor cells exist in adult
human and mouse islets (Smukler et al. 2011), which are
proportionally increased in the small, extra-islet clusters
of β cells of young mice (Beamish et al. 2016). Hence, we
sought to determine if this population was also present in
similar extra-islet β-cell clusters in the human pancreas,
as well as to assess how this cell population changes with
age. We have found that the young human pancreas
contains a significant proportion of Ins+Glut2LO cells both
within and outside of the islet, and while this population
decreases with advancing age in both species, such cells
are still present in older adults.
Novel insights have emerged from this study
regarding the pancreas maturation and remodelling at
key developmental times such as birth and adolescence.
A significant proportion of endocrine cell mass is present
in the young human pancreas outside of proto-typical
islet structures, with nearly 45% of β cells present in small
clusters (<5 β cells) during the fetal life, ~30% during
infancy, and ~20% during childhood. This trend was noted
previously (Meier et al. 2008), but not quantified per se. It
could be questioned that if islets were sectioned at the
periphery, then cell grouping size would be theoretically
equivalent to that of the clusters; however, this would be
a relatively rare event, the same bias would be applied
consistently, and if that was true, then these data would
not change with age as seen here. Although it may be
similarly stated that the assignment of 5 or fewer β cells
connoting a cluster is arbitrary, isolated human islets in
transplant procedures are standardized to islet equivalent
(IEQ) sizing, with a diameter of 150 µm, or ~1500 cells in
total (1560 ± 20 cells) (Pisania et al. 2010). Including basic
assumptions of spherical shape, mathematically calculated
as V = 4/3πr2, where r = the number of cells, and 1140/1560
of those cells being β cells, this volume calculation yields
a standard islet diameter of 14.2 cells, or 13.0 β cells, thus
well above our 5 β-cell restriction (which necessarily has
a maximum radius of 2.5 β-cells). Indeed, there is a lack
of consistency in the nomenclature and size metrics in
the literature when quantifying small β-cell aggregates or
clusters. For instance, an ‘islet’ may be identified within
pancreas sections as 4 (insulin-positive) β-cells (together)
(Meier et al. 2008, Jo et al. 2011), in juxtaposition to
‘β-cell clusters’ variably constituting <10 β cells (Dor et al.
2004), or <20 β cells (Van de Casteele et al. 2013) when
quantified by total cell number, or alternatively <50 μm
(Chintinne et al. 2010, 2012) or <60 μm (Kilimnik et al.
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2012) when determined by the β-cell area. Within the
confines of our model, the proportion of β cells present
as single cells/small clusters (i.e., <5 β-cells) outside of
the islet only declines substantially during puberty, and
is thereafter maintained at ~5% in adults. This dramatic
decrease was not seen in mouse, which showed a more
gradual decline after weaning. However, in both species,
β-cell proliferation in the cluster compartment was
extremely low (mouse)/absent (human) by this stage of
development, which may indicate a shift in cell plasticity.
This low rate of β-cell proliferation during adolescence
has been noted previously (Meier et al. 2008), although
not specifically in reference to β cells outside of islets. It
is of interest to note that the incidence of type 1 diabetes
in humans peaks between 10 and 14 years (i.e., puberty/
adolescence) (Gan et al. 2012), which coincides with the
developmental shift to larger islets and fewer β-cell clusters,
as demonstrated here. We propose that in addition to
the demands of somatic growth necessary at this age
(Meier et al. 2008) and the relative insulin resistance
associated with puberty as measured by homeostatic model
assessment (HOMA) (Jeffery et al. 2012), adolescence may
be an especially vulnerable window for diabetes if β-cell
expansion from small clusters is a declining option.
It has been shown by others that the young
human pancreata contain a higher proportion of small
islets relative to large islets than that is found in mice
(Kilimnik et al. 2012). Intriguingly, there is evidence that
small islets are functionally superior to large ones after
transplant (Lehmann et al. 2007, Suszynski et al. 2014).
Although the physiological relevance of extra-islet β
cells in the human pancreas remains to be determined,
the implications of this data are clear: efforts should
be made to retain all β cells, especially within clusters,
for use in human islet transplant preparations. It was
recently shown that islet transplants from young donors
generate superior results, although islet yields are poorer
compared to those from adults (Meier et al. 2014). Data
shown here provide further support for the utilization of
islets specifically from young donors, which we contend
to contain a higher proportion of Ins+Glut2LO β-cell
progenitors present within small islets/β-cell clusters. In
mice, the difference in the Ins+Glut2LO cell population
within β-cell clusters during the immediate postnatal time
period and up to day 21 is consistent with data indicating
a shift in β-cell plasticity after a change in diet at weaning
(Stolovich-Rain et al. 2015).
In the human pancreas the proportional presence of
β cells undergoing replication was reported to be 3.2%
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at the fetal life, 2.5% at birth, and reduced to 0.1% after
6 months of age (Kassem et al. 2000, Meier et al. 2008,
2010). Higher rates of proliferation were noted in small
islets and β cells found scattered throughout the pancreas,
and decreased with age, leading to the conclusion that
larger islets were created both from proliferation as
well as from the coalescence of small clusters (Jo et al.
2011), and that this cluster aggregation decreased with
age (Jeon et al. 2009). By adulthood, there is consensus
that β-cell proliferation is extremely low, at ~0.1–0.5%
(Müller et al. 1990, Meier et al. 2008, Cnop et al. 2010,
Perl et al. 2010). Rates of β-cell proliferation in rodents
have been shown to be similar to those in humans,
with 1–3% β cells replicating at any time in the young
rat (Finegood et al. 1995), but only ~0.2% by adulthood
(Müller et al. 1990, Kushner 2006). Recently this β-cell
proliferation consensus was challenged, with evidence
that the length of time post-mortem that the tissue was
exposed to ischemia negatively affected the number
of cells staining positively for Ki67, thus artificially
minimizing the proliferation rate of adult human β cells
(Sullivan et al. 2015). Our results are consistent with the
observed variability between the young human pancreata;
however, we have shown the rate of β-cell proliferation in
mouse and human in adulthood to be slightly higher than
that reported by others, which may be explained by the
relatively high number of cells examined in this study, the
stringent inclusion criteria of brief human cadaveric cold
ischemia time prior to fixation, as well as the inclusion of
small endocrine clusters. Although we acknowledge that
the Ki67 labelling rate in humans may be underestimated,
the inter-sample variability in adult tissues was not high,
thus lending validity to these findings. Moreover, our
human data was comparable to findings in mice, whose
pancreata were fixed immediately after dissection.
An important question is whether Ins+Glut2LO cells
have a physiological function at times of metabolic
stress or pancreas damage. It is conceivable that β cells
undergo a normal cycle of developmental transition in
glucose-responsiveness, expressing Glut2 in high and
low proportion. Similarly, these cells could be dismissed
as simply senescent β-cells. Neither of those alternative
hypotheses would support the evidence that the
population of Ins+Glut2LO cells decreases with age, or
transiently increases after STZ ablation, as demonstrated
here. Other have shown that human Ins+Glut2LO β cells
within islets obtained from pancreas donors with diabetes
demonstrated a higher differentiation and proliferative
capacity in vitro than that from equivalent cell populations
of non-diabetic donors (Razavi et al. 2014). That study did
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not examine the contribution of Ins+Glut2LO β cells within
clusters, which may represent a larger source of such cells
in vivo, nor examine how the population changes with age.
These cells may be represented within the small clusters
of β cells retained in the pancreata of older ‘Medalist’
donor tissues (Keenan et al. 2010). These data further
substantiate mounting evidence of β-cell heterogeneity,
with newly identified markers being the variable presence
of the antigens ST8SIA and CD9 which stratify β-cells into
4 subsets (Dorrell et al. 2016), the vesicular monoamine
transporter 2 (VMAT2) (Saisho et al. 2008), the Wnt/
planar cell polarity (PCP) gene Flattop (Fltp) (Bader et al.
2016), among others reported (Roscioni et al. 2016). Our
data strongly align with evidence provided by Bader et al,
showing that immature β-cells can be identified by the
lack of Fltp, are more proliferative, and have a significant
reduction in Slc2a2 (GLUT2) gene expression.
We and others have shown that young rodents retain
the capacity to partially regenerate β-cell mass after STZ
ablation, but this regenerative potential is mitigated in
adulthood (Bonner-Weir et al. 1981, Portha et al. 1989,
Wang et al. 1996, Thyssen et al. 2006, Tschen et al. 2009,
Chamson-Reig et al. 2010, Cox et al. 2010, Marchand et al.
2010, Nicholson et al. 2010). This loss of regenerative
capacity coincides with the decline seen here in both
Ins+Glut2LO cell abundance, and a change in their
anatomical location. When we examined the dynamic
changes to Ins+Glut2LO cells during the compensatory
β-cell regeneration that occurs after STZ administration
to young mice, we found a positive association between
the generation of new β cells, particularly in clusters and
smaller islets, and an increased proportional presence of
Ins+Glut2LO cells during the initial stages of regeneration.
This could be consistent with an expansion in number
and subsequent maturation of Ins+Glut2LO cells into
functional β cells as a contributing mechanism to an
adaptive increase in β-cell mass, as proposed by Szabat
and coworkers who showed that β cells can transition
from Pdx1+InsLO to Pdx1+Ins+ cells (Szabat et al. 2009).
This is further supported with evidence from human
Ins+Glut2LO cells in vitro, which showed that diabetes
biased the maturation of those cells into a functional
phenotype (Razavi et al. 2014), as well as aspects of β-cell
lineage tracing experiments of induced pancreatic injury
and regeneration (Liu et al. 2010).
Determining the role of resident Ins+Glut2LO cells
during other pathological circumstances or in times of
increased metabolic demand will further elucidate a
potential role for this cell population in human health
and pancreas development.
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